1h Free Analyst Time
The Osteoporosis Drugs Market size was estimated at USD 8.32 billion in 2023, USD 8.77 billion in 2024, and is expected to grow at a CAGR of 5.60% to reach USD 12.19 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Osteoporosis drugs treat and prevent osteoporosis, a disorder in which bones become brittle and weak, causing them to be more susceptible to fractures. Osteoporosis is a common condition, particularly among postmenopausal women, and it can have serious consequences, including disability and chronic pain. The rising number of the elderly population, increasing awareness of osteoporosis care, and incidence of osteoporosis in postmenopausal women have significantly increased the need for osteoporosis drugs. However, the side effects of osteoporosis drugs and the time-consuming drug approval process hamper the growth of the osteoporosis drugs market. Additionally, the growing investment in drug discovery and the rising number of research activities in healthcare organizations are expected to boost osteoporosis drugs market growth in upcoming years.
Regional Insights
The Americas has a significant landscape in the osteoporosis drugs market owing to the high adoption of advanced technologies, developed healthcare infrastructure, and the high prevalence of osteoporosis. According to the National Osteoporosis Foundation, approximately 10 million Americans have osteoporosis, and another 44 million have low bone density, which increases their risk of developing the condition. Moreover, the collaborative research programs implemented by major health organizations and the development of new products in Europe, the Middle East, and Africa improve the current market environment. Additionally, the market for osteoporosis drugs in APAC is expected to grow significantly due to the increasing incidence of osteoporosis in countries such as Japan, China, and South Korea. According to the International Osteoporosis Foundation, the prevalence of osteoporosis in the Japanese female population aged 50-79 years has been estimated to be about 35% at the spine and 9.5% at the hip. The market is expected to grow in the coming years, driven by factors such as an aging population, increasing awareness about bone health, and the introduction of new and innovative osteoporosis drugs.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Osteoporosis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Osteoporosis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Osteoporosis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alembic Pharmaceuticals Ltd., Alkem Laboratories Ltd., Amgen, Inc., Apotex Inc., Century Pharmaceuticals Ltd., Cipla Ltd., Cubit Healthcare, Dr. Reddy's Laboratories, Eli Lilly and Company, F.Hoffmann La Roche AG, GlaxoSmithKline PLC, Hetero Healthcare Ltd., Intas Pharmaceuticals Ltd, Macleods Pharmaceuticals Ltd., Merck & Co AG, Midas Pharma GmbH, Mylan N.V. by Viatris Inc., Natco Pharma Ltd., Novartis AG, Pfizer Inc., Polpharma, Pulse Pharmaceuticals, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., and Vintage Labs Pvt. Ltd.Market Segmentation & Coverage
This research report categorizes the Osteoporosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:- Drug Type
- Bisphosphonates
- Calcitonin
- Parathyroid Hormone Therapy
- Rank Ligand Inhibitors
- Selective Estrogen Inhibitors Modulator
- Route of Administration
- Injectable
- Oral
- Application
- Primary Osteoporosis
- Secondary Osteoporosis
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Osteoporosis Drugs Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Osteoporosis Drugs Market?
- What are the technology trends and regulatory frameworks in the Osteoporosis Drugs Market?
- What is the market share of the leading vendors in the Osteoporosis Drugs Market?
- Which modes and strategic moves are suitable for entering the Osteoporosis Drugs Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Osteoporosis Drugs Market, by Drug Type
7. Osteoporosis Drugs Market, by Route of Administration
8. Osteoporosis Drugs Market, by Application
9. Americas Osteoporosis Drugs Market
10. Asia-Pacific Osteoporosis Drugs Market
11. Europe, Middle East & Africa Osteoporosis Drugs Market
12. Competitive Landscape
13. Competitive Portfolio
14. Appendix
List of Figures
List of Tables
Companies Mentioned
- AbbVie Inc.
- Alembic Pharmaceuticals Ltd.
- Alkem Laboratories Ltd.
- Amgen, Inc.
- Apotex Inc.
- Century Pharmaceuticals Ltd.
- Cipla Ltd.
- Cubit Healthcare
- Dr. Reddy's Laboratories
- Eli Lilly and Company
- F.Hoffmann La Roche AG
- GlaxoSmithKline PLC
- Hetero Healthcare Ltd.
- Intas Pharmaceuticals Ltd
- Macleods Pharmaceuticals Ltd.
- Merck & Co AG
- Midas Pharma GmbH
- Mylan N.V. by Viatris Inc.
- Natco Pharma Ltd.
- Novartis AG
- Pfizer Inc.
- Polpharma
- Pulse Pharmaceuticals
- Steris Healthcare Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd
- Taj Pharmaceuticals Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vintage Labs Pvt. Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 181 |
| Published | March 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 8.77 Billion |
| Forecasted Market Value ( USD | $ 12.19 Billion |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
